HDAC9 and thoracic cancer: In this study, we attempted to evaluate the possibility of enhancing the cytotoxic effect of VA, a commonly used antiepileptic drug with HDAC-inhibitory activity, on cultured thoracic cancer cells by combining it with the kinase inhibitor STP or its clinically relevant analogue UCN-01.